This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ishikura, F. Articles by Nehra, A. Search for Related Content PubMed PubMed Citation Articles by Ishikura, F. Articles by Nehra, A. Related Collections Coronary circulation Endothelium/vascular type/nitric oxide

(Circulation. 2000;102:2516.)
© 2000 American Heart Association, Inc.

Basic Science Reports

Effects of Sildenafil Citrate (Viagra) Combined With Nitrate on the Heart

Fuminobu Ishikura, MD; Shintaro Beppu, MD; Toshiaki Hamada, BS; Bijoy K. Khandheria, MD; James B. Seward, MD; Ajay Nehra, MD

From the School of Allied Health Sciences (F.I., S.B., T.H.), Osaka University, Faculty of Medicine, Osaka, Japan, and the Division of Cardiovascular Diseases and Internal Medicine (B.K.K., J.B.S.) and the Department of Urology (A.N.), Mayo Clinic and Mayo Foundation, Rochester, Minn.

Background—Sildenafil citrate (Viagra) is indicated for the treatment of erectile dysfunction. Large and sudden decreases in systemic blood pressure were reported in a substantial number of patients taking sildenafil citrate combined with nitroglycerin. We studied the effect of sildenafil citrate on the relationship between changes in systemic blood pressure and coronary blood flow.

Methods and Results—Healthy male beagles were used to assess systemic blood pressure, pulmonary arterial pressure, and flow in the left circumflex artery (in which a critical stenosis was established) and left anterior descending coronary artery. After measurement of the hemodynamic variables, 2 mg/kg sildenafil citrate was administered via a nasogastric tube. Hemodynamic changes were monitored for 1 hour. Subsequently, the acute effect of nitrate combined with sildenafil citrate was studied by the bolus injection of 0.2 mg isosorbide dinitrate before and after sildenafil citrate. Systemic blood and pulmonary arterial pressures and circumflex flow did not change during this study; however, left anterior descending coronary arterial flow increased from 16.0±5.8 to 24.6±8.7 mL/min 1 hour after administration of sildenafil citrate. The prolongation of systemic blood pressure decrease and the circumflex flow decrement induced by isosorbide dinitrate after sildenafil citrate were significantly larger and longer than those before sildenafil citrate.

Conclusions—Sildenafil citrate had the effect of vasodilation in a normal coronary artery; however, a combined effect with nitrate resulted in large and protracted decreases in systemic blood pressure and coronary blood flow in vessels with critical stenosis.

Key Words: blood flow • coronary disease • sildenafil citrate

This article has been cited by other articles:

				G. Szabo, T. Radovits, G. Veres, N. Krieger, S. Loganathan, P. Sandner, and M. Karck Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass Eur. J. Cardiothorac. Surg., October 1, 2009; 36(4): 657 - 664. [Abstract] [Full Text] [PDF]

				T. Klein, M. Eltze, T. Grebe, A. Hatzelmann, and M. Komhoff Celecoxib dilates guinea-pig coronaries and rat aortic rings and amplifies NO/cGMP signaling by PDE5 inhibition Cardiovasc Res, July 15, 2007; 75(2): 390 - 397. [Abstract] [Full Text] [PDF]

				S D Robinson, C A Ludlam, N A Boon, and D E Newby Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease Heart, February 1, 2006; 92(2): 170 - 176. [Abstract] [Full Text] [PDF]

				E. Fung, R. R. Fiscus, A. P. C. Yim, G. D. Angelini, and A. A. Arifi The Potential Use of Type-5 Phosphodiesterase Inhibitors in Coronary Artery Bypass Graft Surgery Chest, October 1, 2005; 128(4): 3065 - 3073. [Abstract] [Full Text] [PDF]

				S. G. Raja and S. H. Nayak Sildenafil: Emerging Cardiovascular Indications Ann. Thorac. Surg., October 1, 2004; 78(4): 1496 - 1506. [Abstract] [Full Text] [PDF]

				S. T. Russell, B. K. Khandheria, and A. Nehra Erectile Dysfunction and Cardiovascular Disease Mayo Clin. Proc., June 1, 2004; 79(6): 782 - 794. [Abstract] [PDF]

				T. Reffelmann and R. A. Kloner Therapeutic Potential of Phosphodiesterase 5 Inhibition for Cardiovascular Disease Circulation, July 15, 2003; 108(2): 239 - 244. [Full Text] [PDF]

				G. Jackson and F. Giuliano Moderators' introduction Eur. Heart J. Suppl., December 1, 2002; 4(suppl_H): H1 - H6. [Abstract] [PDF]

				A Tracqui, A Miras, A Tabib, J S Raul, B Ludes, and D Malicier Fatal overdosage with sildenafil citrate (Viagra1): first report and review of the literature Human and Experimental Toxicology, November 1, 2002; 21(11): 623 - 629. [Abstract] [PDF]

				E. A. Bocchi, G. Guimaraes, A. Mocelin, F. Bacal, G. Bellotti, and J. F. Ramires Sildenafil Effects on Exercise, Neurohormonal Activation, and Erectile Dysfunction in Congestive Heart Failure: A Double-Blind, Placebo-Controlled, Randomized Study Followed by a Prospective Treatment for Erectile Dysfunction Circulation, August 27, 2002; 106(9): 1097 - 1103. [Abstract] [Full Text] [PDF]

				A. M. Arruda-Olson, D. W. Mahoney, A. Nehra, M. Leckel, and P. A. Pellikka Cardiovascular Effects of Sildenafil During Exercise in Men With Known or Probable Coronary Artery Disease: A Randomized Crossover Trial JAMA, February 13, 2002; 287(6): 719 - 725. [Abstract] [Full Text] [PDF]